Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Pharmacokinetics, Pharmacodynamics (PK/PD), and Safety Profile of Ulviprubart: Results from a 48-week, Open-label, Phase 1 Study in Patients with Inclusion Body Myositis (IBM)

              Author:Needham, Merrilee   Henderson, Robert D.   Liang, Christina   Soler-Ferran, Dulce   Wilkins, H. Jeffrey   Greenberg, Steven A.   

              Session Name:P3: Neuromuscular and Clinical Neurophysiology (EMG): Acquired and Genetic Muscle Disorders  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:P3.012  

              Author Institution:Perron Institute, QEII Medical Centre  University of Notre Dame  Fiona Stanley Hospital  Murdoch University, Western Australia, Australia  Department of Neurology, Royal Brisbane & Women's Hospital  University of Queensland Centre for Clinical Research, University of Queensland, Queensland, Australia  Royal North Shore Hospital, Sydney Medical School, New South Wales, Australia